Literature DB >> 22157856

Translating discoveries into medicine: psychiatric drug development in 2011.

Linda S Brady1, Thomas R Insel.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22157856      PMCID： PMC3238058          DOI： 10.1038/npp.2011.106

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  9 in total

Review 1.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

3.  Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.

Authors:  Thomas Insel; Bruce Cuthbert; Marjorie Garvey; Robert Heinssen; Daniel S Pine; Kevin Quinn; Charles Sanislow; Philip Wang
Journal:  Am J Psychiatry       Date:  2010-07       Impact factor: 18.112

4.  A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

Authors:  Maria C N Marchetto; Cassiano Carromeu; Allan Acab; Diana Yu; Gene W Yeo; Yangling Mu; Gong Chen; Fred H Gage; Alysson R Muotri
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

5.  Modelling schizophrenia using human induced pluripotent stem cells.

Authors:  Kristen J Brennand; Anthony Simone; Jessica Jou; Chelsea Gelboin-Burkhart; Ngoc Tran; Sarah Sangar; Yan Li; Yangling Mu; Gong Chen; Diana Yu; Shane McCarthy; Jonathan Sebat; Fred H Gage
Journal:  Nature       Date:  2011-04-13       Impact factor: 49.962

6.  From animal models to model animals.

Authors:  Thomas R Insel
Journal:  Biol Psychiatry       Date:  2007-12-15       Impact factor: 13.382

7.  Could pharma open its drug freezers?

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

8.  Development of novel combination therapies.

Authors:  Janet Woodcock; Joseph P Griffin; Rachel E Behrman
Journal:  N Engl J Med       Date:  2011-02-16       Impact factor: 91.245

Review 9.  Drug targets for cognitive enhancement in neuropsychiatric disorders.

Authors:  Tanya L Wallace; Theresa M Ballard; Bruno Pouzet; Wim J Riedel; Joseph G Wettstein
Journal:  Pharmacol Biochem Behav       Date:  2011-04-01       Impact factor: 3.533
  9 in total
  9 in total

1.  Innovation in therapeutics development at the NCATS.

Authors:  Christine M Colvis; Christopher P Austin
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

Review 2.  Emotion and Theory of Mind in Schizophrenia-Investigating the Role of the Cerebellum.

Authors:  Omar Mothersill; Charlotte Knee-Zaska; Gary Donohoe
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

3.  Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders.

Authors:  Timothy P Spicer; Christopher Hubbs; Thomas Vaissiere; Deanna Collia; Camilo Rojas; Murat Kilinc; Kyle Vick; Franck Madoux; Pierre Baillargeon; Justin Shumate; Kirill A Martemyanov; Damon T Page; Sathya Puthanveettil; Peter Hodder; Ronald Davis; Courtney A Miller; Louis Scampavia; Gavin Rumbaugh
Journal:  Mol Neuropsychiatry       Date:  2017-11-17

4.  PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Authors:  David E Kemp; Martha Schinagle; Keming Gao; Carla Conroy; Stephen J Ganocy; Faramarz Ismail-Beigi; Joseph R Calabrese
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

5.  Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.

Authors:  Alkomiet Hasan; Astrid Roeh; Stefan Leucht; Berthold Langguth; Maximilian Hansbauer; Tatiana Oviedo-Salcedo; Sophie K Kirchner; Irina Papazova; Lisa Löhrs; Elias Wagner; Isabel Maurus; Wolfgang Strube; Moritz J Rossner; Michael C Wehr; Ingrid Bauer; Stephan Heres; Claudia Leucht; Peter M Kreuzer; Stephanie Zimmermann; Thomas Schneider-Axmann; Thomas Görlitz; Susanne Karch; Silvia Egert-Schwender; Beate Schossow; Philipp Rothe; Peter Falkai
Journal:  Contemp Clin Trials Commun       Date:  2020-01-28

6.  Future directions for research in autism spectrum disorders.

Authors:  Cara R Damiano; Carla A Mazefsky; Susan W White; Gabriel S Dichter
Journal:  J Clin Child Adolesc Psychol       Date:  2014

7.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

Review 8.  Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnerships.

Authors:  Christine A Livingston; Kristin M Fabre; Danilo A Tagle
Journal:  Comput Struct Biotechnol J       Date:  2016-05-10       Impact factor: 7.271

9.  Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk.

Authors:  Donald F Smith
Journal:  Front Psychiatry       Date:  2013-06-18       Impact factor: 4.157
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.